Drug intelligence / Profile preview

MMV688533

Development stage: Phase 1
Lead developer: Medicines for Malaria Venture
Modality: Small Molecules
Administration: Oral

Overview

MMV688533 is a novel, long-acting antimalarial small molecule developed by the Medicines for Malaria Venture (MMV). It functions as a potent inhibitor of the *Plasmodium falciparum* acetyl-CoA synthetase (PfAcAS), an enzyme essential for the parasite's metabolic processes, including fatty acid synthesis and survival. The compound is designed to be fast-acting and long-lasting, with the potential to serve as a component of a single-dose cure for malaria. Clinical development has focused on evaluating its safety, tolerability, and antimalarial activity against blood-stage *P. falciparum* infections in healthy volunteers using the Induced Blood Stage Malaria (IBSM) challenge model.

Other names: MMV533MMV-533MMV 533

Targets

PfEHD (Plasmodium falciparum EHD protein)AC (Adenylyl cyclase family)

Beyond the preview

Go deeper on MMV688533.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MMV688533.

Explore the full profile